Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Poll Shows Incidence, Adverse Effects of Cancer-Related Fatigue

March 1, 1997
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 3
Volume 6
Issue 3

NEW YORK--A nationwide survey of US cancer patients, oncologists, and caregivers documents that fatigue has profound effects on patients, including their ability to work, meet family needs, and cope with the disease.

NEW YORK--A nationwide survey of US cancer patients, oncologists, andcaregivers documents that fatigue has profound effects on patients, includingtheir ability to work, meet family needs, and cope with the disease.

The survey, of 419 patients, 197 oncol-ogists, and 200 caregivers, showedthat 78% of cancer patients experience fatigue during the course of theirdisease, with 53% saying they experience fatigue on most days, if not everyday (Figure 1).

While 80% of physicians surveyed said they believe that fatigue is overlookedand undertreated, less than half reported that they discuss it with patientsor attempt to treat it.

"For many patients, fatigue is a daily reminder that they havecancer," said Nicholas Vogelzang, MD, professor of medicine, Universityof Chicago, and one of the authors of the survey. "If we can controlor lessen its effects, we go a long way toward restoring a sense of normalcyto patients' lives."

Some Too Tired to Eat

The survey was conducted by the research organization Wirthlin Worldwidefor The Fatigue Coalition, a multidiscipli-nary group of physicians andpatient advocates from institutions including Harvard, Stanford, MemorialSloan-Kettering, the University of Chicago, and the National Coalitionfor Cancer Survi-vorship. It was underwritten by Ortho Biotech Inc.

The majority of cancer patients reported that fatigue adversely affectstheir ability to work (61%) and interferes with their usual activities(51%), while 42% said that it negatively impacts their ability to takecare of their families (see Figure 2).For some, fatigue makes it difficult even to get out of bed (29%) or toeat their meals (24%).

Psychologically, fatigue also takes a tremendous toll: 57% of patientsin the study said they are unable to enjoy life fully because of fatigue,and 31% said that fatigue affects their hope of successfully fighting theircancer. Some 16% of patients surveyed said that treating their fatiguewas as important as treating the cancer itself, a "small althoughrelevant figure," Dr. Vogelzang said.

Other intriguing findings: While physicians believe that pain is moredebilitating and prevalent than fatigue, 61% of patients say that fatigueaffects their lives more than pain. And while most patients feel that fatigueis caused by their treatment, most physicians believe that the cancer isthe cause, which may explain why most patients (75%) are resigned to livingwith their fatigue.

In response to the survey, The Fatigue Coalition plans to develop aseries of educational and research initiatives designed to help patientsand physicians better understand the onset, duration, and progression offatigue in cancer and how to intervene successfully.

Articles in this issue

Bills Address Women's Health and Cancer Issues
Possible Evolutionary Advantage Seen in Breast Cancer Genes
Physicians Urged to Listen to Tamoxifen Users' Concerns
Neck Check Exam Aims at Early Detection
Upcoming Multicenter Study Will Compare Digital Versus Film Screen Mammography
Investigation Clears Fisher of Scientific Misconduct Charges In NSABP Studies

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.

WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care

Russ Conroy
September 13th 2025
Article

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 13th 2025
Podcast

The second takeaway is that the type of responses and efficacy that we have seen with these combinations rival what we have in our standard of care armamentarium.

How Promising Are Immunotherapy Combos in Indolent Lymphoma?

Tim Cortese
September 13th 2025
Article

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 13th 2025
Podcast

We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.

Understanding Predictive Markers Drives Ruxolitinib Usage in Myelofibrosis

Tim Cortese
September 13th 2025
Article

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 13th 2025
Article
Related Content

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.

WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care

Russ Conroy
September 13th 2025
Article

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 13th 2025
Podcast

The second takeaway is that the type of responses and efficacy that we have seen with these combinations rival what we have in our standard of care armamentarium.

How Promising Are Immunotherapy Combos in Indolent Lymphoma?

Tim Cortese
September 13th 2025
Article

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 13th 2025
Podcast

We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.

Understanding Predictive Markers Drives Ruxolitinib Usage in Myelofibrosis

Tim Cortese
September 13th 2025
Article

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 13th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.